Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 5;8(7):e68149.
doi: 10.1371/journal.pone.0068149. Print 2013.

Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion

Jing Feng  1 , Tong Zhao, Yan Zhang, Yan Ma, Yanrong Jiang
Affiliations

Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion

Jing Feng et al. PLoS One. .

Abstract

Purpose: This study investigates the differential aqueous concentrations of interleukin 6, 8, 1β (IL-6, IL-8, IL-1β, respectively), serum amyloid A (SAA), transforming growth factor (TGF)-β, basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) in eyes with macular edema as a result of a branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Principal findings: Significantly higher concentrations of IL-6, IL-8, IL-1β, TGF-β, bFGF, SAA, and VEGF were found in the aqueous humor of CRVO and BRVO patients than in the aqueous humor of control patients. A significant correlation was observed between the concentration of bFGF and the inner central macular thickness (CMT) of BRVO patients (r = 0.688; P = 0.02). A significant correlation was observed between the concentration of SAA and both the full and outer CMT of the ischemic group (r = 0.545 and 0.683, respectively; P = 0.04 and 0.01, respectively). In the non-ischemic group, the level of IL-6 was significantly associated with inner CMT (r = 0.560; P = 0.03). The full and outer CMT was significantly reduced in CRVO patients when compared with BRVO patients (P = 0.02 and 0.02, respectively) after injection of intravitreal bevacizumab (IVB) at 4 weeks.

Significance: Serum amyloid A as a major protein involved in the acute and chronic stages of inflammation, and IL-6 and bFGF were significantly associated with the extent of macular edema in patients with RVO. Besides VEGF, other inflammatory cytokines and angiogenesic factors may be associated with RVO. This finding may have implications for the medical treatment of RVO.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Scatterplot showing the association between the inner central macular thickness and the aqueous bFGF after the decadic logarithm transformation in in patients with macular edema resulting from BRVO, with a statistically significant correlation between the parameters(r = .688; P = .02).
Figure 2
Figure 2. Scatterplot showing the association between the full central macular thickness and the aqueous SAA after the decadic logarithm transformation in in patients with macular edema resulting from ischemic RVO, with a statistically significant correlation between the parameters(r = .545; P = .04).
Figure 3
Figure 3. Scatterplot showing the association between the outer cental macular thickness and the aqueous SAA after the decadic logarithm transformation in in patients with macular edema resulting from ischemic RVO, with a statistically significant correlation between the parameters(r = .683; P = .01).
Figure 4
Figure 4. Scatterplot showing the association between the inner cental macular thickness and the aqueous IL-6 after the decadic logarithm transformation in in patients with macular edema resulting from non-ischemic RVO, with a statistically significant correlation between the parameters(r = .560; P = .03).
See this image and copyright information in PMC

References

    1. Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98: 133–141. - PMC - PubMed
    1. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, et al. (2009) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147: 298–306. - PubMed
    1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, et al. (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117: 313–319. - PMC - PubMed
    1. Clarkson JG (1994) Central Vein Occlusion Study: photographic protocol and early natural history. Trans Am Ophthalmol Soc 92: 203–213; discussion 213–205. - PMC - PubMed
    1. Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124: 726–732. - PubMed

Publication types

LinkOut - more resources